Introduction {#S1}
============

The number of people affected by neurodegenerative diseases has been increasing significantly over the last few decades, due to the ever-growing world population and an increase in life expectancy. Age is a major risk factor for neurodegeneration, hence the number of patients will further increase and become a major health issue worldwide. This is further aggravated by the lack of effective prevention and/or disease-modifying treatment strategies for these disorders. Drug discovery efforts are thus a priority ([@B33]; [@B23]).

Many neurodegenerative diseases, such as Alzheimer's, Parkinson's, and Huntington's as well as other polyglutamine diseases, including Machado-Joseph disease (MJD), or Spinocerebellar ataxia type 3 (SCA3) have in common their association with aging, protein aggregation and oxidative stress ([@B28]; [@B35]). In both familiar and sporadic forms of PD, mitochondrial dysfunction, neuroinflammation and environmental factors contribute to the susceptibility of dopaminergic neurons. When the production of Reactive Oxidative Species (ROS) surpasses the cellular antioxidant activity, the continuation of an oxidation state triggers cellular damage and causes neuronal loss, a process that is generally linked to normal aging but accelerated in disease states ([@B8]). The involvement of oxidative stress in MJD is less well documented, however, it is thought that ATXN3 plays an important role in regulating the FOXO4-dependent antioxidant stress response *via* the manganese superoxide dismutase (SOD2), which is disrupted upon expression of the mutant protein. This suggests that a decreased antioxidative capacity and an increased susceptibility toward oxidative stress contribute to neuronal cell death in MJD ([@B3]). In fact, MJD patients show decreased antioxidant defense capacity, as a result of increased ROS generation and decreased levels of glutathione peroxidase ([@B20]), as well as reduced thiol levels (glutathione and thioredoxins) and increased DNA damage ([@B47]). This suggests that approaches to improve the cellular antioxidant capacity could lead to effective therapeutics.

Previous research on plant extracts and isolated compounds from plants (natural products) had shown promising results in both *in vitro* and *in vivo* models of normal aging ([@B50]) as well as in models of neurodegenerative diseases ([@B33]; [@B23]; [@B49]). HPLC-MS/MS analysis of RSP extracts revealed the presence of different secondary metabolites, such as phenolic acids, benzaldehydes, amines, indoles, flavonoids and coumarins, sinapine being the most abundant secondary metabolite ([@B48]; [@B66]). Sinapine is a known acetylcholinesterase inhibitor due to its structural similarity to acetylcholine ([@B25]) and has neuroprotective effects and lifespan increasing properties in several model systems ([@B38]; [@B65]; [@B27]). We have previously shown the antioxidant and radical scavenging activity of the ethanolic rapeseed pomace (RSP) extract *in vitro*. In addition to the *in vitro* antioxidant activity, both the RSP extract and sinapine exhibited acetylcholinesterase inhibition activity and protected plasmid DNA from oxidative stress induced DNA damage *in vitro* ([@B48]; [@B66]).

Our previous results suggested the direct antioxidant activity of the RSP extract. Direct antioxidants are redox active, short-lived and are consumed or chemically modified during the process of their antioxidant activity. They need to be regenerated or replenished for continuous activity. However, at certain concentrations they can also show pro-oxidant activity ([@B22]). In comparison, indirect antioxidants can activate antioxidant pathways, e.g., Kelch Like ECH Associated Protein 1/Nuclear factor (erythroid-derived 2)-like 2/antioxidant response elements (Keap1/Nrf2/ARE) in humans. This causes transcriptional induction of a variety of cytoprotective proteins, also known as phase II detoxification enzymes. For the activation of these pathways, the indirect antioxidants are not sacrificed and hence have a longer half-life ([@B22]; [@B18]). Different indirect antioxidants have been found in plants, such as curcumin in turmeric, carnosol and carnosic acid in the herb rosemary ([@B43]; [@B56]) and sulforaphane which is found in plants of the *Brassicaceae* family such as broccoli, cauliflower and cabbage ([@B22]; [@B59]). While inducing cytoprotective proteins, some indirect antioxidants also act as direct antioxidants. By doing so they fulfill both roles, they can decrease ROS immediately and induce responses, which might have cytoprotective effects over a longer period of time ([@B22]).

In this work, to determine the *in vivo* antioxidant activity of RSP extract and its potential for the prevention of neurodegenerative diseases, the model organism *C. elegans* was used. Due to its numerous advantages (easy of culture in large numbers, a short life span and a well characterized nervous system, as well as its amenability to genetic manipulation and its transparency, even in adult stages), it is commonly used in neuroscience-related studies ([@B1]; [@B16]; [@B41]). We focused on two neurodegenerative disease -- PD and MJD -- that have been associated with intracellular protein aggregation and in which oxidative stress has proven to be relevant. *C. elegans* models for both disorders have previously been created and employed for the search of potential treatments ([@B57], [@B58]; [@B37]; [@B42]) and were used here to test the therapeutic potential of RSP extract, as a first *in vivo* evidence.

Materials and Methods {#S2}
=====================

Strains and General Maintenance {#S2.SS1}
-------------------------------

A list of strains together with their abbreviations, genotype and source is given in [Supplementary Table S1](#SM1){ref-type="supplementary-material"}. All strains were cultured and observed using standard methods ([@B10]) unless otherwise stated. *C. elegans* grew on Nematode Growth Medium (NGM) plates seeded with *Escherichia coli* OP50 strain at 20°C. All the strains were backcrossed to Bristol strain N2 six to eight times. The UA44 (Pdat-1:GFP; Pdat-1:α-syn) and UA57 (Pdat-1:GFP; Pdat-1:CAT-2) strains were generously provided by Guy Caldwell (University of Alabama). The MJD related strains (AT3q14, AT3q75, and AT3q130) were previously described ([@B57]) and double mutant strains \[AT3q130;gst-4(ko) and α-syn;gst-4(ko)\] were generated using common breeding techniques ([@B24]). The remaining strains were provided by the Caenorhabditis Genetics Center (CGC).

Rapeseed Pomace Extracts and Sinapine {#S2.SS2}
-------------------------------------

The RSP extract was prepared as previously described ([@B48]; [@B66]). Although our previous studies have shown small batch-to-batch variability in chemical composition in extracts from different harvest years ([@B48]), in this work several extractions were performed, and the obtained extracts collected, combined, homogenized, vacuum packed and stored at −80°C. Sinapine thiocyanate was obtained from ChemFaces, China (CFN90624) and was used without further purification.

*C. elegans* Drug Toxicity Assay {#S2.SS3}
--------------------------------

The toxicity of distinct concentrations of RSP extract *in vivo* was determined in the wild-type N2 Bristol strain, using the food clearance assay ([@B60]). The assay was performed as previously described ([@B60]; [@B58]) in liquid culture in 96-well plate format using concentrations from 0.01--5.0 mg/mL of RSP extract and 0.001--1.0 mg/mL sinapine, using DMSO as the drug vehicle at a final concentration of 1%. Animals treated with 1% and 5% DMSO were used as a non-toxic (vehicle control) and as a toxic concentration control, respectively.

Motor Performance and Mutant ATXN3 Aggregation in the *C. elegans* MJD Model Treated With RSP Extract {#S2.SS4}
-----------------------------------------------------------------------------------------------------

AT3q130 animals were treated with concentrations of RSP extract and sinapine ranging from 0.1 to 5.0 mg/mL and 0.001--1.0 mg/mL, respectively, in liquid culture in 96-well format as described for the toxicity assay ([@B60]). The motility assay was performed as previously described ([@B57]), using *C. elegans* strains expressing WT (AT3q14) and mutant ATXN3 (AT3q130) proteins in their nervous system, as well as N2 as control. *In vivo c*onfocal dynamic imaging and quantification of mutant ATXN3 aggregates for the RSP extract treatment was conducted as previously described ([@B57]) using an Olympus FV1000 (Japan) confocal microscope, under a 60x oil (*NA* = 1.35) objective. Z-series images were acquired for vehicle (1% DMSO) and RSP extract-treated (4 mg/mL) animals, using a 515 nm laser excitation line for yellow fluorescent protein (YFP). Regarding quantification of the mutant ATXN3 aggregates, two parameters were measured: area of aggregates/total area and number of aggregates/total area in three repeated experiments. The RSP extract concentration chosen for the *in vivo* imaging (4 mg/mL) was based on the initial motility results.

Quantitative Analysis of Dopaminergic Neuronal Degeneration in the 6-OHDA *C. elegans* PD Model Treated With RSP Extract {#S2.SS5}
------------------------------------------------------------------------------------------------------------------------

The experimental procedure for 6-hydroxydopamine (6-OHDA) exposure was adapted from [@B13] with minor modifications, using the strain BZ555 that expresses green fluorescent protein (GFP) in all dopaminergic neurons. Briefly, an age synchronized egg population was obtained *via* bleaching ([@B55]). Approximately 200 eggs were pipetted onto NGM plates, freshly seeded with freeze/thaw inactivated OP50 containing DMSO (1%, vehicle control) or RSP extract (4 mg/mL) (day 0). Approximately 48 h later (day 2), L2-L3 worms were washed off the plates and washed 2--3 times in distilled water (dH~2~O) containing 1% Luria broth (LB) until solution was clear (no remaining OP50). Worms were resuspended in approximately 500 μL of dH~2~O with 1% LB. In a 12-well plate, 250 μL of 6-OHDA (final concentrations 10 and 25 mM), 250 μL ascorbic acid (final concentrations 2 and 5 mM, respectively) and 500 μL of the worm solution were incubated for 1 h at ∼50 rpm on a Grant-Bio POS-300 orbital shaking platform. After this time, the worms were diluted and washed 2--3 times in dH~2~O with 1% LB. Thereafter, BZ555 worms were transferred back onto respective vehicle or RSP extract seeded plates. On day 5, approximately 72 h after 6-OHDA treatment, worms were prepared for confocal imaging, as described above. Dopaminergic (DAergic) neurons were counted in 10--12 animals and representative pictures of each condition were obtained. The experiment was repeated three times (total number of worms scored *n* ≥ 30).

Quantitative Analysis of Dopaminergic Neuronal Loss in Alpha-Synuclein and CAT-2-Mediated PD Model Treated With RSP Extract {#S2.SS6}
---------------------------------------------------------------------------------------------------------------------------

Age-synchronized populations of BZ555 (Pdat-1:GFP), UA44 (Pdat-1:GFP; Pdat-1:α-syn) and UA57 (Pdat-1:GFP; Pdat-1:CAT-2) strains were obtained *via* egg-laying. Briefly, gravid animals were picked onto plates seeded with freeze/thaw inactivated OP50 supplemented with vehicle (1% DMSO) and RSP extract (4 mg/mL) and left to lay eggs for 1--2 h before being removed from plates (day 0). After day 3, animals were transferred daily to fresh plates to avoid progeny. At day 7 and/or 10, worms (*N* = 10--12) were prepared for confocal microscopy as described above. Intact dopaminergic (DAergic) neurons were counted, and representative pictures of each condition were taken. The experiment was repeated independently three times (total number of worms scored *n* ≥ 30).

Assessment of Antioxidant Response Induction Using Reporter Strains for *gst-4*, *sod-3* and *gcs-1* Genes {#S2.SS7}
----------------------------------------------------------------------------------------------------------

CL2166 \[(pAF15)gst-4p:GFP:NLS\], CF1553 \[(pAD76) sod-3p:GFP + rol-6(su1006)\], LD1171 \[(gcs-1p:GFP + rol-6(su1006)\] strains were grown in NGM plates seeded with freeze/thaw inactivated bacteria and RSP extract (4 mg/mL) until day 4 (∼96 h after hatching). Worms were prepared for fluorescence microscopy, by preparing 3% agar slides and adding a drop of sodium azide (2 mM) in addition to 10--12 worms per slide. Worms were oriented using an eye lash, excess azide was removed and the worms were covered with a cover slide and sealed with 3% agar. Brightfield (1.662 ms exposure time, ISO1600) and fluorescence (ISO1600, GFP filter) images of vehicle and RSP extract treated animals were acquired in an Olympus Microscope BX61 (10× objective) using the same respective settings. Fluorescence exposure time was set to a value where vehicle treated worms were barely visible and the same settings were used to analyze the RSP treated worms. Fluorescence intensity of each worm was measured using Fiji (ImageJ, 1.51n), divided by the total area of the respective animal and normalized to the mean of the vehicle treated worms. The experiment was repeated three times independently, *n* ≥ 10 being the number of animals analyzed per treatment in each experiment (per condition). For the purpose of showing the results, the same level of brightness and contrast was applied to vehicle- and RSP-treated animals, with no impact in the fluorescence quantification of the images.

Statistical Analysis {#S2.SS8}
--------------------

All statistical analyses were performed using GraphPad Prism 7 (Version 7.01) or SPSS 25.0 (SPSS Inc.). Continuous variables were tested for normal distribution (Shapiro--Wilk or Kolmogorov--Smirnov normality test), for homogeneity of variance (Levene's test) and outliers; and were then analyzed with one-way or two-way ANOVA, using Bonferroni's, Dunnett's or Tukey's multiple comparison analysis for *post hoc* comparison. Non-continuous variables were analyzed through non-parametric Mann--Whitney or Kruskal--Wallis (with Bonferroni's multiple comparison correction) tests, for two or more groups, respectively. For the comparison of effect sizes of RSP extract and sinapine treatments of experiments undertaken in independent trials, the Hedge's test was done in R (version 3.6.1, package "effsize" version 0.7.6). A critical value for significance of *p* ≤ 0.05 was applied throughout the study. All experiments were run at least in triplicate (*n* ≥ 3) and data presented are showing mean ± standard deviation unless otherwise stated.

Results {#S3}
=======

RSP Extract Shows No Toxic Effect in *C. elegans* {#S3.SS1}
-------------------------------------------------

RSP extract safety concentration range in *C. elegans* was determined by the food clearance assay ([@B60]). A compound is considered safe to *C. elegans* if it causes no changes in animal growth, survival, and number of offspring, which can be measured indirectly by determining the rate of food consumption of the *E. coli* bacteria (OP50). The profile of the bacteria optical density curves obtained for all the tested concentrations of the RSP extract resembled that of vehicle treated animals (1% DMSO control, known to be safe) ([@B58]; [Figure 1](#F1){ref-type="fig"}). The OP50 food source was cleared in an expected manner, starting on day 2--3 when worms were on the L4 molt. The further decrease in optical density on day 4 was associated with an increased number of worms in the wells, due to the appearance of progeny. There was no change in bacteria density upon 5% DMSO treatment, confirming its toxic effects. In summary, the RSP extract was considered safe to *C. elegans* at concentrations up to 5 mg/mL.

![RSP extract (0.01--5.0 mg/mL) shows no toxic effect in *C. elegans*. Toxicity was assessed using the food clearance assay. The optical density of the OP50 suspension with RSP extract-treated animals (N2) at the concentrations depicted, was measured daily. The mean optical density (OD) was calculated for each day from triplicate samples and plotted over time. Control DMSO (1%) corresponds to drug vehicle and DMSO at 5% was used as positive (toxic compound) control, *n* = 5 (independent experiments).](fnins-13-01091-g001){#F1}

Improvement of Motor Impairments of an MJD *C. elegans* Model With RSP Extract Treatment Independently of ATXN3 Aggregation Load {#S3.SS2}
--------------------------------------------------------------------------------------------------------------------------------

To determine whether the RSP extract supplementation has therapeutic value for MJD, we used a *C. elegans* model of ATXN3 neurotoxicity (AT3q130) in which mutant ATXN3 proteins expressed in neurons, caused motility defects and aggregation ([@B57]). The results presented in [Figure 2A](#F2){ref-type="fig"} demonstrated a concentration-dependent improvement in motility of the RSP-treated AT3q130 animals. Concentrations ranging from 1.00--5.00 mg/mL showed a very strong and significant improvement (*p* ≤ 0.001). However, lower concentrations of 0.75 mg/mL (*p* ≤ 0.01) and 0.50--0.25 mg/mL (*p* ≤ 0.05) also significantly improved the animals' motor capacity. Only the lowest RSP extract concentration of 0.1 mg/mL showed no effect on the phenotype when administered to the animals. Treatment of AT3q130 animals with RSP extract at 4 mg/mL restored their motor function close to the level of WT ATXN3 expressing animals (AT3q14), hence this concentration was used in further experiments. To determine whether this motility improvement was disease specific, we also treated WT (N2) and AT3q14 animals with 4 mg/mL of RSP extract. The results confirmed a disease-specific effect since neither the N2 nor the AT3q14 motor performance changed upon treatment ([Figure 2B](#F2){ref-type="fig"}).

![Improvement of motor impairments of the MJD *C. elegans* model with RSP extract treatment is independent of ATXN3 aggregation load. **(A)** Locomotion defective behavior of MJD (AT3q130) animals, comparison between treated (RSP extract 0.1--5.0 mg/mL), untreated animals (1% DMSO solvent control), wild type (N2) and AT3q14 controls (1% DMSO). Statistical significant difference was determined using One-way ANOVA and Dunnett's multiple comparison analysis compared to AT3q130 control: ^∗∗∗^*p* ≤ 0.001, ^∗∗^*p* ≤ 0.01, ^∗^*p* ≤ 0.05; *n* = 5. **(B)** Comparison of locomotion defective behavior of N2, AT3q14, and AT3q130 untreated (1% DMSO vehicle control) and RSP extract treated (4 mg/mL) animals. Statistical significant difference determined using Two-way ANOVA and Tukey's multiple comparisons test compared to untreated (1%DMSO) control: ^∗∗∗^*p* ≤ 0.001, ns-not significant, *n* = 6. **(C)** Confocal imaging of head region of AT3q130 strain treated with RSP (4 mg/mL, right) in comparison to vehicle control (1% DMSO, left). Confocal microscopy pictures are representative for the three independent experiments. **(D)** Aggregation load (number and area of aggregations) of AT3q130 animals upon treatment with RSP extract (4 mg/mL) compared to solvent control (1% DMSO). Values shown are the mean (normalized to vehicle treated control) of 10 or more animals per group; number of experiments *n* = 3, no significant difference, *p* \> 0.05 (unpaired *t*-test). Data normalized to the 1% DMSO control. Scale bar 50 μm in all represented pictures.](fnins-13-01091-g002){#F2}

As sinapine has been determined to be the most abundant compound present in the RSP extract ([@B66]), we next tested it for toxicity and disease modifying properties in AT3q130 animals. Sinapine showed no toxicity toward *C. elegans* up to 1 mg/mL ([Supplementary Figure S1A](#SM1){ref-type="supplementary-material"}) and had a beneficial effect in the disease model, although its effect in motility improvement was smaller (Hedge's *g* = −3.967) than the RSP extract (Hedge's *g* = −5.585) ([Supplementary Figure S1B](#SM1){ref-type="supplementary-material"} and [Figure 2A](#F2){ref-type="fig"}), suggesting that additional components of the extract are contributing to its therapeutic effect. Hence, subsequent analyses were carried out using the whole RSP extract.

In MJD, the mutant ATXN3 (mATXN3) protein forms aggregates within affected regions of the patient's brain. This is also observed in the *C. elegans* AT3q130 model ([@B57]), which shows mATXN3 aggregation in neuronal cells in the head region as well as in the dorsal and ventral nerve cords of the animals. Confocal imaging revealed no significant change in the number or area of mATXN3 protein aggregates in the head of treated animals compared to the untreated animals ([Figures 2C,D](#F2){ref-type="fig"}), which demonstrates an uncoupling of RSP extract effect between these two main hallmarks of MJD, neuronal dysfunction and mutant protein aggregation.

RSP Extract Treatment Protects From 6-OHDA-Induced Dopaminergic (DAergic) Neuronal Loss {#S3.SS3}
---------------------------------------------------------------------------------------

Given the promising results in the polyglutamine disease model described above, the effect of the RSP extract was next evaluated in a chemically induced model of PD. Transgenic animals expressing GFP proteins under the regulation of the dopamine transporter promoter (P*dat-1*:GFP) in all 8 hermaphrodite dopaminergic (DAergic) neurons ([Figure 3A](#F3){ref-type="fig"}) were exposed to a mixture of 6-OHDA and ascorbic acid (as stabilizer) for 1 h. After 72 h, animals treated with 10 and 25 mM of 6-OHDA showed a clear loss of DAergic neurons ([Figures 3B,C,F](#F3){ref-type="fig"}), compared to vehicle-treated control animals ([Figures 3A,F](#F3){ref-type="fig"}) (*p* ≤ 0.001): *in vivo* dynamic imaging showed intact cell bodies and processes of the DAergic neurons of vehicle-treated GFP-expressing animals ([Figure 3A](#F3){ref-type="fig"}), contrasting with a 6-OHDA concentration dependent increase in the blobbing of neuronal processes, and in the loss of cell bodies ([Figures 3B,C](#F3){ref-type="fig"}). The four cephalic neurons (CEPs) were most susceptible to 6-OHDA treatment ([Supplementary Figure S2](#SM1){ref-type="supplementary-material"}).

![Protective effects of RSP extract supplementation (4 mg/mL) on DAergic neurodegeneration in *C. elegans*. *C. elegans* strain with GFP expression in all DAergic neurons (Pdat-1:GFP) grown in media supplemented with 1% DMSO (solvent control) and treated with **(A)**: 0 mM 6-OHDA and 0 mM AA, **(B)**: 10 mM 6-OHDA and 2 mM AA, **(C)**: 25 mM 6-OHDA and 5 mM AA. *C. elegans* strain expressing GFP proteins in all DAergic neurons (Pdat-1:GFP) grown in media supplemented with **(D,E)** 4 mg/mL RSP extract pre- and post- treated with **(D)**: 10 mM 6-OHDA and 2 mM AA, **(E)** 25 mM 6-OHDA and 5 mM AA. The fluorescence signals of DAergic neurons in the animals' head (CEPs and ADEs) were photographed at 60× magnification using confocal fluorescence microscopy. Scale bar 50 μm in all represented pictures. **(F)** Total number of DAergic neurons were scored for each condition. Data are expressed as the median ± 10--90 percentile, with results obtained from three independent experiments (*n* = 3 with ≥ 10 animals per treatment). Significant differences between conditions were determined by non-parametric Kruskal--Wallis test and outlier analysis. ^\#^*p* \< 0.05, ^\#\#\#^*p* \< 0.001 compared with vehicle alone (no 6-OHDA), ns, ^∗^*p* \< 0.05, ^∗∗^*p* \< 0.01, and ^∗∗∗^*p* \< 0.001 compared with respective 6-OHDA concentration control. 6-OHDA: 6-hydroxydopamine; AA: ascorbic acid; DAergic-dopaminergic neurons.](fnins-13-01091-g003){#F3}

When comparing the 1% DMSO with the 4 mg/mL RSP extract treated worms, there was a clear beneficial effect of the treatment ([Figures 3B--E](#F3){ref-type="fig"}) for both 6-OHDA concentrations. Upon supplementation with RSP extract, more animals showed intact cell bodies and processes, although in some neurons the rounding of the cell body ([Figure 3](#F3){ref-type="fig"}, arrowheads) was still visible upon treatment. This was confirmed when analyzing the total number of DAergic neurons ([Figure 3F](#F3){ref-type="fig"}) as well as the CEP neurons alone ([Supplementary Figure S1](#SM1){ref-type="supplementary-material"}). These results suggest that supplementation with RSP extract protects against toxin-induced loss of DAergic neurons *in vivo*.

RSP Extract Treatment Prevents DAergic Neuronal Loss in Genetic Models of PD {#S3.SS4}
----------------------------------------------------------------------------

We then tested the effect of RSP extract treatment in genetically modified nematodes that were also previously described to mimic various aspects of PD neuropathology. Expression of human α-synuclein proteins (α-syn), in combination with GFP proteins, in the 8 *C. elegans* DAergic neurons induced neuronal death at day 7 and 10 of life ([@B13]; [@B19]; [@B11]). Overexpression of *cat-2*, a gene which encodes tyrosine hydroxylase, the limiting enzyme for dopamine synthesis in *C. elegans*, leads to increased intracellular levels of dopamine ([@B13]). As with α-synuclein, its overexpression is known to cause the degeneration of DAergic neurons in older animals. In *cat-2* overexpression animals, loss of DAergic neurons can also be detected by the co-expression of GFP in DAergic neurons ([@B13]; [@B44]).

Control animals expressing only GFP proteins in all DAergic neurons showed the presence of most neurons as well as the 4 dendrites associated with the 4 CEP neurons, heading to the front of the worm ([Figures 4A,B](#F4){ref-type="fig"}; 7 days old animals and [Figures 4G,H](#F4){ref-type="fig"} 10 days old animals). In contrast, animals overexpressing α-syn and CAT-2 proteins showed a significant loss of DAergic neurons and their processes on days 7 ([Figures 4A,C,D](#F4){ref-type="fig"}) and 10 ([Figures 4G,I,J](#F4){ref-type="fig"}). Animals treated with RSP extract for the duration of the experiment, showed an increase in the number of preserved DAergic cell bodies and dendrites, in particular for the CEPs, at day 7 ([Figures 4A,E,F](#F4){ref-type="fig"}) and 10 ([Figures 4G,K,L](#F4){ref-type="fig"}) indicating that the RSP extract treatment suppresses DAergic neuronal loss in the genetic PD model, as seen in the chemically induced model.

![Supplementation with RSP extract suppressed loss of DAergic neurons mediated by alpha-synuclein and tyrosine hydroxylase overexpression in *C. elegans*. Confocal imaging and quantification of total number of DAergic neurons in Pdat-1:GFP animals (**A**, day 7 and **G**, day 10), in Pdat-1:GFP; Pdat-1:α-syn (**B**, day7 and **H**, day 10) and in Pdat-1:GFP; Pdat-1:cat-2 (**C**, day7 and **I**, day 10) vehicle treated (1% DMSO) animals, as well as in Pdat-1:GFP; Pdat-1:α-syn (**D**, day7 and **J**, day 10) and in Pdat-1:GFP; Pdat-1:cat-2 (**E**, day 7 and **K**, day 10) RSP extract (4 mg/mL) treated animals. Quantification of total number of DAergic neurons is shown in **F** (day 7) and **L** (day 10). Confocal microscopy pictures represent the head region of *C. elegans* and the pictures are representative of three independent experiments. Data is shown as the median ± 10--90 percentile with results obtained from three independent experiments (*n* = 3 with ≥ 10 animals per treatment). Significant differences between strains and treatment were determined by Kruskal--Wallis analysis, after outlier analysis: ns no significant difference. ^\#\#\#^*p* \< 0.001 compared with Pdat-1:GFP; ns ^∗∗∗^*p* \< 0.001 compared with respective vehicle treated strain control. Scale bar 50 μm in all represented pictures.](fnins-13-01091-g004){#F4}

Activation of Antioxidant Pathways by RSP Extract Treatment {#S3.SS5}
-----------------------------------------------------------

To test the hypothesis that the antioxidant properties of the RSP extract may contribute to the observed neuroprotective effect in *C. elegans* models of neurodegenerative diseases, we determined whether the RSP extract had the potential to activate antioxidant pathways, using *C. elegans* reporter strains for the *gst-4*, *gcs-1* and *sod-3* genes. GST-4 which encodes for the drug-metabolizing enzyme glutathione S-transferase 4 and *gcs-1*, the phase II detoxification enzyme gamma-glutamyl cysteine synthetase, are involved in glutathione metabolism and biosynthesis, respectively. Both genes are downstream targets of the transcription factor SKN-1 (Nrf-2 ortholog) ([@B30]). *sod-3* codes for the mitochondrial manganese superoxide dismutase, which converts the ROS superoxide into hydrogen peroxide. The transcriptional activity of these genes was measured indirectly by the expression of GFP. The results showed a modest but significant induction of the transcriptional activity of the *sod-3* gene promoter upon RSP treatment ([Figures 5A,D](#F5){ref-type="fig"}). P*gst-4*:GFP animals show a three-fold induction of GFP fluorescence upon RSP extract treatment ([Figures 5B,D](#F5){ref-type="fig"}), but no changes in the *gcs-1* promoter activity of Pgcs-1:GFP animals ([Figures 5C,D](#F5){ref-type="fig"}) were observed in treated animals when compared with vehicle.

![RSP extract supplementation activated transcriptional activity of *gst-4* and *sod-3*, but not of *gcs-1* gene promoters in *C. elegans* reporter strains. Brightfield and widefield fluorescence images of vehicle-(1% DMSO) and RSP-(4 mg/mL) treated Psod-3:GFP **(A)**, Pgst-4:GFP **(B)** and Pgcs-1:GFP **(C)** animals. Graphical results shown in **(D)** represents the GFP fluorescence intensity divided by the total area of each worm (*n* ≥ 9) normalized to the respective 1% DMSO control. Statistical comparison was done via two-way ANOVA and Bonferroni's multiple comparisons test after Shapiro--Wilk normality test and outlier analysis, graph shows a representative example of three experimental replicates (*n* = 3). ns, no significant difference and ^∗∗∗^*p* \< 0.001 compared with respective control. The pictures presented are from the same experimental day. Time of exposure is maintained constant in vehicle- and RSP-treated animals. Fluorescence intensity of each worm was measured using Fiji (ImageJ, 1.51n) and divided by the total area of the respective animal and normalized to the mean of the vehicle treated worms. Scale bar 100 μm in all represented pictures.](fnins-13-01091-g005){#F5}

Suppression of α-Synuclein- and Mutant ATXN3-Mediated Neurotoxicity by RSP Extract Treatment Is Dependent on GST-4 {#S3.SS6}
------------------------------------------------------------------------------------------------------------------

To determine whether the beneficial effects of RSP extract treatment in the *C. elegans* models of PD and MJD pathogenesis were mediated by GST-4, we assessed the effect of RSP extract supplementation in a *gst-4* deletion background \[*gst-4(ko)*\]. Ablation of *gst-4 per se* did not alter the α-syn-mediated neuronal loss ([Figure 6A](#F6){ref-type="fig"}) or mutant ATXN3-mediated motor impairments ([Figure 6B](#F6){ref-type="fig"}). However, RSP extract treatment failed to suppress α-syn-mediated loss of DAergic neurons in the absence of *gst-4* ([Figure 6A](#F6){ref-type="fig"}), suggesting the importance of GST-4 activity in the extract's mechanism of action.

![GST-4-dependent rescue of MJD and PD phenotypes by RSP extract supplementation. **(A)** DAergic neuron loss in Pdat-1:GFP, Pdat-1:α-syn and in Pdat-1:α-syn;gst-4(ko) animals comparing treated (RSP extract (4 mg/mL) and untreated \[DMSO (1%)\] conditions. Graph: 2 independent experiments (n) were conducted with 12 animals per group. Statistical significant difference was determined using the non-parametric Kruskal--Wallis test ^∗^*p* \< 0.05 compared to untreated α-syn, ^\#\#\#^*p* \< 0.001 compared to Pdat-1::GFP, ns compared to untreated α-syn;gst-4(ko). Images: confocal imaging of DA neurons, scale bar 50 μm. **(B)** Motility assay comparison between WT, AT3q130, AT3q130; gst-4(ko) and gst-4(ko) strains. At least 200 animals were assayed per experiment, in five independent experiments (*n* = 5). Significant differences between strains and treatment were determined by one-way ANOVA and Bonferroni's multiple comparison analysis, after Shapiro--Wilk normality test and outlier analysis: ^∗∗∗^*p* \< 0.001 compared with respective control.](fnins-13-01091-g006){#F6}

A similar analysis made on AT3q130 animals in the background of *gst-4* ablation \[AT3q130; *gst-4(ko)*\] ([Figure 6B](#F6){ref-type="fig"}) also indicated the role of GST-4 activation in the positive effect of the RSP extract in this disease model. AT3q130 animals showed significant motility improvements upon RSP extract treatment (4 mg/mL), whereas the AT3q130; *gst-4(ko)* double mutants showed no significant improvement in motor capacity compared to the vehicle control (1% DMSO). Taken together, these results support the idea that neuroprotection and suppression of proteotoxicity by RSP extract supplementation is dependent on the modulation of GST-4 activity in *C. elegans*.

Discussion {#S4}
==========

In this study we describe the potential use of RSP extract to prevent neuronal dysfunction and neurodegeneration *in vivo* using transgenic *C. elegans* strains expressing mutant ATXN3, α-synuclein and tyrosine hydroxylase to mimic MJD and PD pathogenesis, respectively. In support of the findings, the loss of DAergic neurons was also rescued by RSP supplementation in a well-established toxin-induced model of PD. These models were previously employed to search potential treatments for these disorders, which were then proven effective in higher model organisms ([@B57], [@B58]; [@B42]; [@B64]).

Although MJD and PD are distinct clinical entities, they share common etiologies, such as the formation of protein aggregates ([@B21]) and some neuropathological mechanisms, including their link to mitochondrial dysfunction, oxidative stress and endoplasmic reticulum stress ([@B14]; [@B15]). Increasing evidence suggested a possible interaction between proteins that have been classically associated to distinct neurodegenerative diseases ([@B63]; [@B36]). Some of these diseases also share clinical and neuropathological features, an example being the slow movement or bradykinesia, that characterizes PD patients, and is also part of the clinical presentation of a subset of MJD patients. Some MJD patients also present parkinsonism with a positive response to levodopa (L-DOPA) ([@B7]). Furthermore, α-synuclein aggregates were detected in the *substantia nigra* of MJD models ([@B2]; [@B45]). This evidence suggests that common molecular and cellular pathways might underlie similarities between disease phenotypes, and that therapeutic compounds targeting those common aspects may be effective for both diseases.

Our study revealed a consistent neuroprotective effect of RSP extract in different models. In MJD, RSP extract supplementation restored motor function of the mutant ATXN3 animals, although not linked to a change in the ATXN3 aggregation load detected in live neurons. This dissociation between the impact on neuronal dysfunction and on ATXN3 aggregation was previously seen in a small molecule drug library screening based on the same animal model ([@B58]), and is consistent with many previous findings supporting such a dissociation for this and other polyglutamine diseases ([@B53]; [@B6]). Sinapine treatment contributes to the attenuation of the motor impairments of mutant ATXN3-expressing animals upon RSP supplementation, however, other components of the extract may also play a role, with potential synergic effects.

To our knowledge there have been no previous reports on the preventive effect of RSP extract in *C. elegans* models of neurodegenerative disease. However, other plant extracts and compounds isolated from plants have been investigated in *C. elegans* PD models. For example, the natural occurring polyamine spermidine rescued α-synuclein-induced loss of DAergic neurons ([@B11]), through autophagy induction. A methanolic extract of red seaweed (*Chondrus crispus*) ([@B51]) showed promising neuroprotective effects and decreased α-synuclein aggregation in muscle cells. These effects were associated with enhanced tolerance to oxidative stress but not to heat stress and with increased expression of *sod-3* and *skn-1*, the *C. elegans* ortholog of Nrf2 ([@B39]). In a MPP^+^-induced PD model, the extract of Korean mountain ash (*Sorbus alnifolia)* restored *C. elegans* viability and prevented neuronal loss ([@B17]). That extract also showed neuroprotection upon CAT-2 overexpression, but with no impact on α-synuclein aggregation ([@B17]).

Studies using natural occurring compounds for the potential treatment of polyglutamine diseases are less common. However, epigallocatechin-3-gallate (EGCG, a tea catechin) suppressed mutant ATXN3-mediated neurotoxicity with no impact on aggregation ([@B9]). The natural product icariside II, a flavonol extracted from the *Epimedium* plant family, in contrast, ameliorated protein aggregation and proteotoxicity-mediated paralysis in a polyQ35 *C. elegans* model and increased the levels of *sod-3* and of *hsp-12.3*, a small heat shock protein that was described to prevent aggregate formation ([@B12]). Other plant secondary metabolites that induce the expression of GST-4 and of other enzymes involved in glutathione biosynthesis and metabolism, also reduce ROS accumulation, protect against oxidative stress and prolong organism lifespan ([@B31]; [@B46]).

Overall, the impact of natural compounds on proteotoxicity has been primarily associated to their antioxidant properties since many studies reported activation of antioxidant genes/pathways. However, those studies fail to show a dependence of these proteins on their therapeutic role. Here, we report the induction of GST-4 expression by RSP extract and the lack of efficacy of RSP supplementation upon GST-4 ablation. Nevertheless, we do not exclude the role of additional cellular targets (e.g., SOD-3, other GSTs and other pathways), neither do we imply a direct dependency on the antioxidant activity of GST-4 *in vivo* on the therapeutic role of RSP extract. Endogenous modification of the catalytic domain/residue of GST-4 (e.g., by using CRISPR) would be necessary ([@B4]; [@B52]) for further elucidation. Other possible mechanisms of action remain to be tested for the RSP extract, including their role in the maintenance of the protein homeostasis capacity in neuronal cells ([@B5]) or in the increase of dopamine D2-like receptor (DOP2R) activation/availability ([@B42]). To further understand the alteration the RSP extract is causing in transgenic *C. elegans* strains and to elucidate its role in MJD and PD, multi-omics combination including metabolomics, transcriptomics and proteomics would be a worthy strategy to adopt in the future.

In humans, glutathione transferases play crucial functions in the metabolism of xenobiotics and of endogenous compounds. In addition to their role in the detoxification of oxidative stress products, GST are also involved in the degradation of aromatic amino acids, synthesis of steroid hormones, synthesis and inactivation of eicosanoids and in the modulation of signaling pathways through their role in the metabolism of endogenous lipid mediators (reviewed in [@B29]). The proposed human ortholog of GST-4 is hematopoietic prostaglandin D synthase (HPGDS) (Wormbase (Version WS272))^[1](#footnote1){ref-type="fn"}^. This is a bifunctional enzyme of the sigma class of the glutathione-S-transferase family and catalyzes the conversion of PGH2 to PGD2 as well as the conjugation of glutathione with a number of electrophilic compounds ([@B34]; [@B32]; [@B26]). GSTs have also been linked to a number of neurodegenerative diseases. In post-mortem brain samples of Alzheimer's disease patients, GST activity and protein levels were significantly decreased, especially in the amygdala, the hippocampus, the inferior parietal lobule and the nucleus basalis of Meynert ([@B40]). Furthermore, in a Drosophila PD model, genetic studies revealed that parkin mutants with additional (loss-of-function) mutations of GSTS1 genes \[a sigma class GST ([@B54])\] caused a worse neurodegenerative phenotype than the parkin mutant itself ([@B61]). On the other hand, over-expression of GSTS1 in DAergic neurons suppressed neurodegeneration and hence, suggested a protective effect of these antioxidant enzymes in PD. Whether GST-4 in *C. elegans* has the same bifunctionality as seen for HPGDS is so far unclear and needs further research.

Despite the accumulation of evidence confirming the role of oxidants in several pathological conditions, most of the antioxidants developed for clinical use have been proven inconclusive or demonstrated limited success. This could be due to the fact that clinical trials include patients at broad stages of disease and therefore distinct severity of symptoms, as well as from different environmental and genetic backgrounds ([@B49]). The investigation of other sources of antioxidants, like RSP, and their application in earlier stages of disease progression and/or as a therapeutic adjuvant, as well as a closer monitoring of clinical trial design may improve therapeutic outcomes.

In conclusion, the RSP extract was shown to have positive effects *in vivo* in *C. elegans* models in a GST-4 dependent manner. This enzyme could constitute a viable therapeutic target for neurodegenerative diseases. For validation of this hypothesis prospective studies on the use of RSP extract or of the single compounds most prevalent in the extract, i.e., sinapine in vertebrate models of MJD and PD in comparison to other plant extracts should be conducted.
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